Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?
Pfizer isn't out of the woods yet, but it is proving it remains a well-run drugmaker.
Pfizer has raised its 2026 revenue forecast by $1.5 billion, which could attract high-risk investors. The company's dividend yield of 5.8% is significantly higher than the broader market's 1% and the average pharmaceutical stock's 1.3%. Pfizer's shares have fallen 50% from their 2021 high, but the company has a history of success and developed a COVID vaccine quickly during the pandemic.
However, Pfizer faces challenges due to patent expirations and new drug development plans. The company is also without a GLP-1 weight-loss drug, which was dropped in 2025. Despite these challenges, investors should wait for further progress in drug development before buying Pfizer. Nonetheless, the company's turnaround effort is going better than expected, and its worst-case scenario for 2026 has been avoided.
Overall, Pfizer remains a well-run drugmaker, but investors should be aware that the road ahead is still difficult. A 50% dividend cut would still result in an above-average yield.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
